Clinical Trials Browser

Phase 2 × Urinary Bladder Neoplasms × Immunohistochemistry × Clear all

NCT01118351 2019-05-01

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Phase 2 Terminated

19 enrolled 11 charts

Urinary Bladder Neoplasms

NCT01118039 2013-08-07

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

Phase 2 Unknown

Urinary Bladder Neoplasms, Urethral Neoplasms